Pharma: Walking the tight rope? - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Pharma: Walking the tight rope?

Oct 3, 2006

The rupee has depreciated considerably against the US Dollar (by around 7%) since the high of Rs 43.28 it had reached on May 11, 2005. While a weaker rupee is definitely a major plus point for export-oriented sectors such as software, pharma and textiles, for pharma companies in particular, it could prove to be a double-edged sword. In this article, we shall try to find out why. Since the domestic pharma market is highly fragmented, most of the Indian pharma companies (excluding the MNCs) are placing a considerably higher thrust on exports. The introduction of the product patent law and the considerable potential in generics in the global market has also aided the increased emphasis on exports. Also, amongst global markets, the major focus areas of companies have been the US and countries in the European region. This means that depreciation in the Indian currency against the dollar and even the Euro is definitely a huge positive for pharma companies.

Export contribution to sales
Company % of sales
Ranbaxy 80%
Cipla 47%
Sun Pharma 39%
Wockhardt 70%
Glenmark 38%

That said, there is also a flip side to the same. It must be noted that due to the intense competition in the US and certain European generics markets, severe price erosion has dented realisations and consequently, margins of companies. Therefore, in a bid to remain competitive, global generic companies are looking to acquire scale and therefore, consolidation in the sector has been heating up. Domestic pharma companies have also emerged as frontrunners in the global acquisitions arena.

On one hand, valuations and consideration to be paid for the targeted company has inched higher (there are many companies vying for the same potential takeover target). On the other hand, domestic companies are not in a position to pay the entire consideration either through cash or internal accruals. This has prompted them to raise funds either through debt or equity. One popular trend that has emerged is raising funds through the FCCB route. And this is where the hitch lies. This is because depreciation in the Indian currency unit will lead to an increase in the value of FCCBs and also a rise in the interest obligations thereby affecting profitability.

In the case of zero-coupon FCCBs (which have also gained popularity), while companies do not have to pay interest, payment pressures (magnified further by the rupee depreciation) could arise during the time of redemption. Of course, if the price of the stock moves ahead of the conversion price, and the bonds are converted into equity, then the company is obviously relieved of the obligation to pay interest or for that matter face redemption pressures.

FCCBs: The hot thing...
Company Amount (US$ m) Conversion price (Rs) Purpose
Ranbaxy 440 713 For funding Terapia and other acquisitions
Sun Pharma 350 729 For future acquisitions
Wockhardt 110 486 For future acquisitions
Glenmark 100 - N.A

To sum up...
We do believe that the Indian Rupee will be weaker against the greenback in the long-term (2% to 3% per annum is a possibility). Given this backdrop, on an overall basis, increased thrust on exports is most likely to offset the negative impact of foreign borrowings for pharma companies. Besides, companies that have not yet utilized the funds for acquisitions have parked the issue proceed with banks overseas thereby generating income. Whatever the case, besides a strong growth in overall exports, pharma companies need to focus on gaining maximum synergies from the acquisitions that they have made to contribute to the overall performance and justify the high valuations. More importantly, at the end of the day, while it is not easy to completely eliminate forex risks, it all boils down to what prudent risk management measures pharma companies are adopting to hedge against the same.

Equitymaster requests your view! Post a comment on "Pharma: Walking the tight rope?". Click here!


More Views on News

CAMS IPO: Should You Apply? (IPO)

Sep 18, 2020

Does the company having 70% market share of the mutual fund registrar business have sound prospects?

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...

Sundaram Bluechip Fund: Will Hold the Stable Horses (Outside View)

Sep 18, 2020

PersonalFn briefly outlines the newly launched NFO note HSBC Corporate Bond Fund.

Wait! Don't Chase Smallcaps Now (Profit Hunter)

Sep 18, 2020

Let the markets take a breather before you jump in.

How Much Money Do You Need to Be a Professional Trader? (Fast Profits Daily)

Sep 17, 2020

In this video I'll answer a question I get asked often: How much capital do I really need to trade the markets for a living? Let's find out...

More Views on News

Most Popular

How the 8-Year Cycle Can Help Identify Multibaggers (Fast Profits Daily)

Sep 11, 2020

This is how you can apply the greed and fear cycle in the market to pick stocks.

I Recommended this Stock over Page Industries because it's Relevant to Doubling Your Income (Profit Hunter)

Sep 7, 2020

Things are not often what they seem in the market and how you can take advantage of this.

The NASDAQ Whale Could Harm Your Portfolio (Fast Profits Daily)

Sep 7, 2020

The discovery of Softbank pushing up prices on the NASDAQ will cause volatility in the market. Stay alert!

This Could Be the Best September for Auto Stocks (Profit Hunter)

Sep 11, 2020

Here's why I think this month could be a great for auto stocks.


Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms


Sep 18, 2020 03:37 PM